Prosecution Insights
Browse Companies Examiners Firms Draft Your Response
Office Actions › Dana-Farber Cancer Institute Inc. › 17419965
Last updated: August 17, 2026
Application No. 17/419,965

SMALL MOLECULE DEGRADERS OF FKBP12 VIA RECRUITMENT OF VON HIPPEL-LINDAU E3 UBIQUITIN LIGASE (VHL) E3 UBIQUITIN LIGASE, AND USES IN dTAG SYSTEMS

Final Rejection
Filed
Jun 30, 2021
Priority
Jan 07, 2019 — provisional 62/789,230 +2 more
Examiner
YOO, SUN JAE
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Dana-Farber Cancer Institute Inc.
OA Round
2 (Final)
71%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
71%
With Interview

Interview Optional

— +0.3% interview lift. Interview already conducted in this application's prosecution history. This examiner has a 71% grant rate with +0.3% interview lift. Since an interview has already been tried, recommend written response with narrowed claims based on precedent claim evolution patterns.
Based on 1234 resolved cases, 2023–2026

Examiner Intelligence

YOO, SUN JAE View full profile →
Grants 71% — above average
71%
Career Allowance Rate
876 granted / 1234 resolved
+11.0% vs TC avg
Minimal +0% lift
Without
With
+0.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
111 currently pending
Career history
1296
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
17.0%
-23.0% vs TC avg
§102
27.6%
-12.4% vs TC avg
§112
33.8%
-6.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1234 resolved cases

Prosecution Timeline

Show 2 earlier events
Sep 19, 2024
Response Filed
Apr 08, 2025
Response Filed
Oct 14, 2025
Response after Non-Final Action
Oct 21, 2025
Applicant Interview (Telephonic)
Oct 23, 2025
Examiner Interview Summary
Feb 13, 2026
Non-Final Rejection mailed
May 11, 2026
Response Filed
Jul 14, 2026
Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

17/423,422
Patent 12692253
Antimicrobial Compounds and Methods
5y 0m to grant Granted Jul 28, 2026
18/289,449
Patent 12690381
ORGANOMETALLIC COMPOUND AND APPLICATION THEREOF
2y 8m to grant Granted Jul 21, 2026
17/618,591
Patent 12674026
PROCESS FOR PREPARING POLYOL-BASED ESTERS OF ACYL-CAPPED HYDROXY CARBOXYLIC ACIDS
4y 6m to grant Granted Jul 07, 2026
17/401,378
Patent 12661353
SPT5 INHIBITORS AND USES THEREOF
4y 10m to grant Granted Jun 23, 2026
18/643,948
Patent 12662459
METHOD FOR THE SYNTHESIS OF 3-R-1,4,2-DIOXAZOL-5-ONES
2y 2m to grant Granted Jun 23, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
71%
Grant Probability
71%
With Interview (+0.3%)
2y 8m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1234 resolved cases by this examiner. Grant probability derived from career allowance rate.

Ready to respond to this office action?

IP Author drafts your complete OA response — amendments, arguments, and claim strategy — in minutes, not days.

Start Drafting Your Response →

Data sourced from USPTO Patent File Wrapper (daily) and Office Action Archive (weekly). Analysis generated by IP Author.

Data: USPTO Patent File Wrapper (daily) • Office Action Archive (weekly) • 89M+ prosecution events

© 2026 IP Author — Browse Office Actions • Examiners • Companies • Firms

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month